$TPIV’s Ready to TAP the Immunology Market
October 5th, 2009 at 6:02 am Posted by
The Dean’s so ecstatic about teaching the CollegeStock Community about $TPIV because it’s more than some biotechnology company—$TPIV‘s developing immunotherapies that fight cancer and have already proven to strengthen the immune system to ward off HIV, Smallpox and other infectious diseases.
Less than a month ago, Johnson & Johnson (NYSE: JNJ) acquired assets and rights to Elan Corporation’s (NYSE: ELN) immunotherapy program for $885 million. Elan’s immunotherapy products proved to slow the progression of Alzheimer’s and has products that treat and prevent other diseases.
What’s so special about this? The Dean thinks a partial buyout like this could be HUGE for a company like $TPIV because they also have technologies which can be applied to a number of deadly and life-threatening diseases.
And the Elan and Johnson & Johnson deal wasn’t the only big deal in the immunotherapy market lately. On September 9, 2009, Immuron (IMC.AX) acquired intellectual property rights for Hadasit’s oral immunotherapies for a 19.99% stake of Immuron—approximately 47 million shares or $3.4 million.
Although this deal was smaller in scale, The Dean thinks it represents the profit potential in $TPIV because companies are realizing that teaming up and combining technologies could put them closer to fighting cancer and infectious diseases.
President Obama’s Recovery Act has received a lot of attention lately because his administration just approved $5 billion worth of medical grants for “cutting-edge medical research.” The Associated Press quotes The White House in saying that this money would be used for “cancer and other diseases” such as “autism, HIV/AIDS, [and] H1N1 Flu.”
The Dean knows that leaves at least $95 billion as part of the government’s stimulus for science and technology—which could mean BIG things for $TPIV and other companies.
The Dean thinks $TPIV is a winner because it’s part of the cancer and vaccine markets. The vaccine market raked in $10 billion in 2007 and is expected to increase by 238% to $23.8 billion within the next year.
And if that doesn’t look GOOD enough for you, the cancer drug market is valued at $75 billion, which is also expected to increase over the next few years to $8o billion—to nearly 4 times the value of the vaccine market for infectious diseases.
Between government funding, cancer therapies and vaccine markets that’s almost $200 billion worth of possibilities for $TPIV. Any questions?
Sign up today and get in at the start of The Dean’s first ever Scholarship Fund contest. To be eligible, you MUST be an Honors Student. With The Dean giving away $5,000 to one top-performing Honors Students every quarter, $9.87/month to register for Honors Class is the ONLY way to get to the head of the class.
